We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




FDA Clears New Blood Test to Aid in Diagnosis of Mastocytosis

By LabMedica International staff writers
Posted on 30 May 2012
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has now approved the use of a tryptase assay to provide a more specific diagnostic tool to physicians suspecting cases of systemic mastocytosis. More...
The assay is also pending approval for use in diagnosing systemic anaphylaxis.

Mastocytosis, the group of rare chronic disorders found in children and adults, is caused by an excess of mast cells, cells normally vital to the inflammatory process and may play protective roles in wound healing and fighting infections. An abnormal burden of the chemicals released from too many of these cells can cause several symptoms ranging in intensity from mild to severe. The symptoms of mastocytosis are often similar to an allergic reaction; however, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The newly approved test, ImmunoCAP Tryptase, measures the level of tryptase in the blood and provides a biochemical indicator on the basis that a persistently elevated baseline level of tryptase is known to be an indication of possible mastocytosis.

The assay was developed by the laboratory led by mast cell expert Lawrence Schwartz, MD, PhD, at Virginia Commonwealth University (VCU; Richmond, VA, USA). Dr. Schwartz, chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas, professor of Medicine at VCU, noted, “A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool.”

VCU first licensed the tryptase assay in 1993 to Pharmacia, now named Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The assay is being further reviewed by the FDA for additional potential applications, including diagnosis of systemic anaphylaxis, prediction of increased risk for future episodes of severe anaphylaxis, and use by medical examiners to evaluate cause of death. “When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death,” said Dr. Schwartz.

Related Links:

Virginia Commonwealth University
Thermo Fisher Scientific, Inc.
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.